Overview

Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well lapatinib ditosylate works in treating patients with metastatic or recurrent head and neck cancer. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Lapatinib